Bench to Bedside Targeting of FLT3 in Acute Leukemia

E-ISSN： 1873-5592|11|7|781-789

ISSN： 1389-4501

Source： Current Drug Targets, Vol.11, Iss.7, 2010-07, pp. : 781-789

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Module for Acute Myelogenous Leukemia Therapy: From Bench to Bedside

Current Medicinal Chemistry, Vol. 14, Iss. 19, 2007-08 ,pp. : 2009-2023

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects

Mini Reviews in Medicinal Chemistry, Vol. 4, Iss. 3, 2004-03 ,pp. : 255-271

Bentham Science Publishers

Access to resources Recommend Favorite

Genomic tools in acute myeloid leukemia: From the bench to the bedside

By White Brian S. DiPersio John F.

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1134-1144

Blackwell Publishing

Access to resources Recommend Favorite

FLT3 as a Therapeutic Target in Childhood Acute Leukemia

Current Drug Targets, Vol. 8, Iss. 6, 2007-06 ,pp. : 703-714

Bentham Science Publishers

Access to resources Recommend Favorite

The clinical development of FLT3 inhibitors in acute myeloid leukemia

By Knapper Steven

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1377-1395

Informa Healthcare

Access to resources Recommend Favorite